Nanobiotix: agreement to restructure its loan agreement with the EIB – 09/12/2022 at 08:55

(AOF) – Nanobiotix has obtained an agreement in principle from the European Investment Bank to restructure 30.7 million euros from the loan agreement signed in 2018. The agreement in principle is structured around cash flows cash envisaged by Nanobiotix around its potential future growth levers, including the hypothesis of the commercialization of NBTXR3 and possible partnerships.

This agreement in principle provides for the deferral of approximately €25.3 million of capital repayments until June 2029 and approximately €5.4 million of capitalized interest payments until October 2024.

It also includes the payment in 2029 of an additional amount limited to a maximum of 20 million euros, the maturity of which could be accelerated if one of these envisaged cash flows were to occur.

The original claim will continue to accrue interest payable until the new due dates. The initiation of the six-year annual royalty period is also postponed to begin on the first commercialization date of NBTXR3.

“Restructuring this EIB loan by extending its maturity date will allow Nanobiotix to focus on its priority NBTXR3 development programs through 2023 while extending its operational capacity by a quarter. With the potential access to additional capital resources at Using the existing equity line, the company’s operational capacity could extend until the first quarter of 2024”, commented art Van Rhijn, chief financial officer of Nanobiotix.


An inevitable race for new blockbusters

The patent for Merck’s star product, the cancer drug Keytruda, which accounts for more than 35% of its sales, expires in 2028. Despite the loss, since 2019, of the patents for its three star products (Avastin, Herceptine, Rituxan) Roche was able to renew its portfolio by bringing new molecules to market. However, the discovery and launch of new drugs are increasingly expensive. AstraZeneca spends about $6 billion a year on R&D in a pharmaceutical industry where the life of a patent only lasts ten to fifteen years. This leads laboratories to withdraw from certain activities. Thus J&J, Pfizer, GSK and, no doubt, Novartis soon prefer to refocus on specialty drugs and abandon any ancillary activity.


Leave a Comment

Your email address will not be published.